Benzinga | Feb 26, 2021 11:17AM EST

Piper Sandler Maintains Overweight on Acceleron Pharma, Raises Price Target to $143

Piper Sandler analyst Christopher Raymond maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $130 to $143.